A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/102 (2006.01) C12N 1/20 (2006.01)
Patent
CA 2542631
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer and cancers of T cell origin, and hyperproliferative diseases involving EphA2- expressing cells. The methods of the invention entail the use of a Listeria- based EphA2 vaccine. The invention also provides pharmaceutical compositions comprising one or more Listeria-based vaccines of the invention either alone in combination with one or more other agents useful for cancer therapy. In certain aspects of the invention, the method entail eliciting both CD4+ and CD8+ T-cell responses against EphA2 and/or EphA2-expressing cells.
La présente invention concerne des méthodes et des compositions mises au point pour le traitement, la gestion ou la prévention de cancers, en particulier le cancer métastatique et les cancers des lymphocytes T, et de maladies hyperprolifératives qui impliquent des cellules exprimant EphA2. Les méthodes de l'invention consistent à utiliser un vaccin EPHA2 à base de listeria. L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs vaccins EPHA2 à base de listeria utilisés seuls ou en association avec un ou plusieurs autres agents utiles pour le traitement du cancer. Dans certains aspects, les méthodes de l'invention consistent à éliciter des réponses des lymphocytes T CD4+ comme des lymphocytes T CD8+ contre les cellules exprimant EphA2.
Bruckheimer Elizabeth
Cook David N.
Dubensky Thomas W. Jr.
Kiener Peter A.
Kinch Michael S.
Cerus Corporation
Medimmune Inc.
Osler Hoskin & Harcourt Llp
LandOfFree
Listeria-based epha2 vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Listeria-based epha2 vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Listeria-based epha2 vaccines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1860196